A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML

Seagen

Status and phase

Completed

Phase 2

Conditions

Acute Myeloid Leukemia

Treatments

Drug: Placebo

Drug: Low dose cytarabine

Drug: Lintuzumab (SGN-33)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00528333

SG033-0003

Details and patient eligibility

About

The purpose of this study is to assess whether there is a survival benefit with lintuzumab given in combination with low dose cytarabine versus low dose cytarabine and placebo in patients with AML.

Enrollment

211 patients

Sex

All

Ages

60+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Untreated AML that occurred de novo, after prior exposure to chemotherapy for a separate malignancy, or evolved from an antecedent hematologic disorder.
After being informed of the potential benefits and risks of available treatment options, patients must have declined intensive chemotherapy for AML.
At least 20% blasts in blood or marrow.
Must have a minimum of 50% leukemic blasts that express CD33.
ECOG performance status score of 0 to 2.
WBC less than 30,000/µL

Exclusion criteria

No known diagnosis of acute promyelocytic leukemia or chronic myeloid leukemia.
No other active systemic malignancies treated with chemotherapy within the last 12 months.
Must not have received previous chemotherapy (except hydroxyurea) for AML.
Must not have significantly abnormal kidney or liver disease.
Must not have known human immunodeficiency virus (HIV).